MOUNTAIN VIEW, Calif., April 28 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq:VVUS - News) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the American Society of Hypertension 25th Annual Scientific Meeting and Exposition in New York, NY. Suzanne Oparil, MD, professor of medicine, physiology and biophysics and director, vascular biology and hypertension program, division of cardiovascular disease, department of medicine at the University of Alabama at Birmingham, will make an oral presentation during the late-breaking clinical trials session entitled: “Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Improves Blood Pressure and Results in Weight Loss in Overweight/Obese Patients Through 28 Weeks.”
